BioPorto A/S (CPH:BIOPOR)
1.134
-0.018 (-1.56%)
At close: Dec 5, 2025
BioPorto Employees
BioPorto had 48 employees as of December 31, 2024. The number of employees increased by 19 or 65.52% compared to the previous year.
Employees
48
Change (1Y)
19
Growth (1Y)
65.52%
Revenue / Employee
761.69K DKK
Profits / Employee
-1.81M DKK
Market Cap
561.44M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 48 | 19 | 65.52% |
| Dec 31, 2023 | 29 | -3 | -9.38% |
| Dec 31, 2022 | 32 | 3 | 10.34% |
| Dec 31, 2021 | 29 | 1 | 3.57% |
| Dec 31, 2020 | 28 | -6 | -17.65% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Novo Nordisk | 77,349 |
| Demant | 22,639 |
| Coloplast | 16,744 |
| GN Store Nord | 7,347 |
| H. Lundbeck | 5,707 |
| Ambu A/S | 5,384 |
| Embla Medical | 4,061 |
| ALK-Abelló | 2,753 |
BioPorto News
- 12 days ago - BioPorto A/S raises approximately DKK 43 million in new capital round - Change in number of shares and votes - GlobeNewsWire
- 17 days ago - BioPorto A/S 2025 Q3 - Results - Earnings Call Presentation - Seeking Alpha
- 22 days ago - Private placement of 40,438,426 new shares fully subscribed – gross proceeds of approximately DKK 43 million to BioPorto A/S - GlobeNewsWire
- 22 days ago - BioPorto Executes on its Financing Strategy- BioPorto A/S initiates pre-subscribed private placement - GlobeNewsWire
- 4 weeks ago - Pre-announcement of the Key Financial Results for Third Quarter 2025 and Revised Guidance for 2025 - GlobeNewsWire
- 2 months ago - BioPorto Sponsors Conferences on Pediatric Critical Care with New NGAL Scientific Data Presented - GlobeNewsWire
- 4 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - GlobeNewsWire
- 4 months ago - BioPorto Interim Result for the Second Quarter of 2025 - Continued progress with full execution of strategic objectives and strong NGAL sales growth. - Benzinga